Lotus Pharmaceutical is set to further expand its oncology and women’s health products while bolting on a fresh ophthalmic and respiratory portfolio and expanding its presence in Southeast Asia after agreeing to acquire Teva’s operations in Thailand.
The Taiwanese firm is targeting completion of the deal in the third quarter of 2024, at which time Teva Pharma Thailand would transition into a wholly owned subsidiary of Lotus and Lotus will undertake
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?